SavedAdd your journal

Journals / İstanbul Kuzey Klinikleri / 2020 / Cilt: 7 - Sayı: 1

A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio

Süleyman SAYAR
Kamil ÖZDİL
Zuhal ÇALIŞKAN
Oğuzhan ÖZTÜRK
Roni ATALAY
Resul KAHRAMAN
Kemal KÜRBÜZ
Hamdi Levent DOĞANAY
Pages
49–55
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When patients were grouped into remission, mild, moderate and severe disease according to disease activity, there wasa statistically significant difference between CRP, CAR, erythrocyte sedimentation rate (ESR) and albumin levels (p=0.001;p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: There are many instruments to measure disease activity in ulcerative colitis.
📊
Key Findings & Data:In this study, we aim to investigate diagnostic performance CAR in determining the clinical severity of ulcerative colitis.METHODS: Between November 2011 and February 2017, hospital records and follow-up cards of patients with ulcerativecolitis were reviewed retrospectively.
💡
Conclusion & Impact:When patients were grouped into remission, mild, moderate and severe disease according to disease activity, there wasa statistically significant difference between CRP, CAR, erythrocyte sedimentation rate (ESR) and albumin levels (p=0.001;p
🔬Design:Review & Systematic Survey
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: There are many instruments to measure disease activity in ulcerative colitis. While determining clinical activityaccording to these instruments, many clinical and laboratory parameters are needed to be followed. Determination of diseaseactivity with non-invasive and objective inflammatory indicators may be a practical and objective way. CRP/Albumin ratio(CAR) is an inflammatory marker that is considered to have prognostic value in various cancers, sepsis and acute pancreatitis. In this study, we aim to investigate diagnostic performance CAR in determining the clinical severity of ulcerative colitis.METHODS: Between November 2011 and February 2017, hospital records and follow-up cards of patients with ulcerativecolitis were reviewed retrospectively. One hundred forty-nine patients were included in this study. Patient’s demographic data,laboratory values, clinical disease activity, according to Truelove & Witts criteria and endoscopic activity according to the Mayosub-score and treatments, were recorded. Diagnostic performance of CAR analyzed to determine the clinical severity.RESULTS: Of the patients included in this study, 99 (62%) were male, and 50 (38%) were female. Mean age was 45.22±14years. When patients were grouped into remission, mild, moderate and severe disease according to disease activity, there wasa statistically significant difference between CRP, CAR, erythrocyte sedimentation rate (ESR) and albumin levels (p=0.001;p

🔖

Cite This Article

SAYAR, S., ÖZDİL, K., ÇALIŞKAN, Z., ÖZTÜRK, O., ATALAY, R., KAHRAMAN, R., KÜRBÜZ, K., DOĞANAY, H. L. (2022). A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. İstanbul Kuzey Klinikleri, Cilt: 7 - Sayı: 1, 49–55. https://ajindex.com/articles/551438

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356–63
  2. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015;110:1324–38
  3. Osterman MT, Lichtenstein GR. Ulcerative Colitis. In: Feldman M, Friedman LS, Brandt JL editors. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. 2016. p. 2023–61
  4. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965–90
  5. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis 2017;11:649–70
  6. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041–8
  7. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905–10
  8. Miranda-García P, Chaparro M, Gisbert JP. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease. Gastroenterol Hepatol 2016;39:508–15
  9. Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol 2016;13:654–64
  10. García-Bosch O, Aceituno M, Ordás I, Etchevers J, Sans M, Feu F, et al. Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study. Dig Dis Sci 2016;61:2051–9
  11. Xu HJ, Ma Y, Deng F, Ju WB, Sun XY, Wang H. The prognostic value of C-reactive protein/albumin ratio in human malignancies: an updated meta-analysis. Onco Targets Ther 2017;10:3059–70
  12. Kaplan M, Ates I, Akpinar MY, Yuksel M, Kuzu UB, Kacar S, et al. Predictive value of C-reactive protein/albumin ratio in acute pancreatitis. Hepatobiliary Pancreat Dis Int 2017;16:424–30
  13. Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C